Eradication of Salmonella Typhimurium infection in a murine model of typhoid fever with the combination of probiotic Lactobacillus fermentum ME-3 and ofloxacin

BMC Microbiology

Volumn 8, Issue , 2008, Pages

  Truusalu, Kai ^a   Mikelsaar, Raik Hiio ^a   Naaber, Paul ^a,b   Karki, Tõnis ^a   Kullisaar, Tiiu ^a   Zilmer, Mihkel ^a   Mikelsaar, Marika ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOBACILLUS FERMENTUM ME 3; LIPID PEROXIDE; OFLOXACIN; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD; CONTROL GROUP; CONTROLLED STUDY; EXPERIMENTAL MODEL; ILEUM MUCOSA; INTESTINE; LIVER GRANULOMA; MONOTHERAPY; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; TYPHOID FEVER; ANIMAL; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; LACTOBACILLUS FERMENTUM; LIVER; MALE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SPLEEN;

ANIMALIA; BACTERIA (MICROORGANISMS); LACTOBACILLUS FERMENTUM; MURINAE; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTOBACILLUS FERMENTUM; LIPID PEROXIDES; LIVER; MALE; MICE; OFLOXACIN; PROBIOTICS; SALMONELLA TYPHIMURIUM; SPLEEN; TYPHOID FEVER;

EID: 50149111623     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-8-132     Document Type: Article

References (28)

1. Enteric (typhoid) fever in travelers. B Basnyat AP Maskey MD Zimmerman DR Murdoch, Clin Infect Dis 2005 41 1467 1472 10.1086/497136 16231259
2. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. DB Huang HL DuPont, Lancet Infect Dis 2005 5 341 348 10.1016/S1473-3099(05)70138-9 15919620
3. Typhoid fever as a rare cause of hepatic, splenic, and bone marrow granulomas. A Mert F Tabak R Ozaras R Ozturk H Aki Y Aktuglu, Intern Med 2004 43 436 439 10.2169/internalmedicine.43.436 15206561
4. Typhoid fever. CM Parry TT Hien G Dougan NJ White JJ Farrar, N Engl J Med 2002 347 1770 1782 10.1056/NEJMra020201 12456854
5. Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Joint FAO/WHO, Cordoba, Argentina 1 to 4 October 2001 http://www.who.int/foodsafety/ publications/fs_management/en/probiotics.pdf
6. Protection from gastrointestinal diseases with the use of probiotics. PR Marteau M de Vrese CJ Cellier J Schrezenmeir, Am J Clin Nutr 2001 73 430S 436S 11157353
7. Probiotics and gastrointestinal diseases. A Sullivan CE Nord, J Intern Med 2005 257 78 92 10.1111/j.1365-2796.2004.01410.x 15606379
8. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. H Szajewska M Setty J Mrukowicz S Guandalini, J Pediatr Gastroenterol Nutr 2006 42 454 475 10.1097/01.mpg.0000221913.88511.72 16707966
9. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. A Tursi G Brandimarte GM Giorgetti ME Modeo, Med Sci Monit 2004 10 CR662 666 15567983
10. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. E Myllyluoma L Veijola T Ahlroos S Tynkkynen E Kankuri H Vapaatalo H Rautelin R Korpela, Aliment Pharmacol Ther 2005 21 1263 1272 10.1111/j.1365-2036.2005. 02448.x 15882248
11. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? M Gotteland O Brunser S Cruchet, Aliment Pharmacol Ther 2006 23 1077 1086 10.1111/j.1365-2036.2006.02868.x 16611267
12. Strain of micro-organism Lactobacillus fermentum ME-3 as novel anti-microbial and anti-oxdative probiotic. M Mikelsaar M Zilmer T Kullisaar H Annuk E Songisepp, US7244424 2007
13. Characterization of intestinal lactobacilli as putative probiotic candidates. H Annuk J Shchepetova T Kullisaar E Songisepp M Zilmer M Mikelsaar, J Appl Microbiol 2003 94 403 412 10.1046/j.1365-2672.2003.01847.x 12588549
14. Two antioxidative lactobacilli strains as promising probiotics. T Kullisaar M Zilmer M Mikelsaar T Vihalemm H Annuk C Kairane A Kilk, Int J Food Microbiol 2002 72 215 224 10.1016/S0168-1605(01)00674-2 11845820
15. Molecular basis of the interaction of Salmonella with the intestinal mucosa. KH Darwin VL Miller, Clin Microbiol Rev 1999 12 405 428 10398673
16. The Influence of Antibacterial and Antioxidative Probiotic Lactobacilli on Gut Mucosa in a Mouse Model of Salmonella Infection. K Truusalu P Naaber T Kullisaar H Tamm R-H Mikelsaar K Zilmer A Rehema M Zilmer M Mikelsaar, Microbial Ecology in Health and Disease 2004 16 180 187 10.1080/08910600410021783
17. Animal models of Salmonella infections: enteritis versus typhoid fever. RL Santos S Zhang RM Tsolis RA Kingsley LG Adams AJ Baumler, Microbes Infect 2001 3 1335 1344 10.1016/S1286-4579(01)01495-2 11755423
18. Salmonella enterica serovar Typhimurium pathogenicity island 2 is necessary for complete virulence in a mouse model of infectious enterocolitis. B Coburn Y Li D Owen BA Vallance BB Finlay, Infect Immun 2005 73 3219 3227 15908346 10.1128/IAI.73.6.3219-3227.2005
19. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. AL Servin, FEMS Microbiol Rev 2004 28 405 440 15374659
20. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. HL Alakomi E Skytta M Saarela T Mattila-Sandholm K Latva-Kala IM Helander, Appl Environ Microbiol 2000 66 2001 2005 10788373 10.1128/AEM.66.5. 2001-2005.2000
21. Involvement of reactive oxygen species in the action of ciprofloxacin against Escherichia coli. M Goswami SH Mangoli N Jawali, Antimicrob Agents Chemother 2006 50 949 954 16495256 10.1128/AAC.50.3.949-954.2006
22. Granulation in livers of mice infected with Salmonella typhimurium is caused by superoxide released from host phagocytes. K Umezawa N Ohnishi K Tanaka S Kamiya Y Koga H Nakazawa A Ozawa, Infect Immun 1995 63 4402 4408 7591077
23. Redefining oxidative stress. DP Jones, Antioxid Redox Signal 2006 8 1865 1879 10.1089/ars.2006.8.1865 16987039
24. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing. P Wayne, Document M100-S16 2006
25. In vivo evaluation of ofloxacin in Salmonella typhimurium infection in mice. KP Fu J Hilliard D Isaacson AJ Tobia JL Rosenthale MCGuire, J Antimicrob Chemother 1990 2 263 8 10.1093/jac/25.2.263
26. A new probiotic cheese with antioxidative and antimicrobial activity. E Songisepp T Kullisaar P Hütt P Elias T Brilene M Zilmer M Mikelsaar, J Dairy Sci 2004 87 2017 2023 15328213
27. Granuloma formation, implications for the pathogenesis of vasculitis. MC Sneller, Cleve Clin J Med 2002 69 Suppl 2 SII40 43 12086263
28. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Griffith OWAB-, Anal Biochem 1980 207 212 10.1016/0003-2697(80)90139-6